1） Fujitani K, Ando M, Sakamaki K, et al: Multicentre observational study of quality of life after surgical palliation of malignant gastric outlet obstruction for gastric cancer. BJS Open 2017; 1: 165‒74.

2） Terashima M, Fujitani K, Ando M, et al: Survival analysis of a prospective multicenter observational study on surgical palliation among patients receiving treatment for malignant gastric outlet obstruction caused by incurable advanced gastric cancer. Gastric Cancer 2021; 24: 224-31.

3） Fujitani K, Yang HK, Mizusawa J, et al: Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non‒curable factor（REGATTA）: a phase 3, randomised controlled trial. Lancet Oncol 2016; 17: 309‒18.

4） Sano T, Sasako M, Mizusawa J, et al: Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg 2017; 265: 277‒83.

5） Tokunaga M, Ohyama S, Hiki N, et al: Therapeutic value of lymph node dissection in advanced gastric cancer with macroscopic duodenum invasion: is the posterior pancreatic head lymph node dissection beneficial? Ann Surg Oncol 2009; 16: 1241‒6.

6） Kurokawa Y, Takeuchi H, Doki Y, et al: Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study. Ann Surg 2021; 274: 120-7.

7） Kurokawa Y, Doki Y, Mizusawa J, et al: Bursectomy versus omentectomy alone for resectable gastric cancer（JCOG1001）: a phase 3, open‒label, randomised controlled trial. Lancet Gastroenterol Hepatol 2018; 3: 460‒8.

8） Sasako M, Sano T, Yamamoto S, et al: Left thoracoabdominal approach versus abdominal‒transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006; 7: 644‒51.

9） Kim HH, Han SU, Kim MC, et al: Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long‒term Survival among Patients with Stage I Gastric Cancer: the KLASS‒01 Randomized Clinical Trial. JAMA Oncol 2019; 5: 506-13.

10）Katai H, Mizusawa J, Katayama H, et al: Survival outcomes after laparoscopy‒assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage ⅠA or ⅠB gastric cancer（JCOG0912）: a multicentre, non‒inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 2020; 5: 142‒51.

11）Katai H, Mizusawa J, Katayama H, et al: Single‒arm confirmatory trial of laparoscopy‒assisted total or proximal gastrectomy with nodal dissection for clinical stage Ⅰ gastric cancer: Japan Clinical Oncology Group study JCOG1401. Gastric Cancer 2019; 22: 999‒1008.

12）Inaki N, Etoh T, Ohyama T, et al: A Multi‒institutional, Prospective, Phase Ⅱ Feasibility Study of Laparoscopy‒Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Locally Advanced Gastric Cancer（JLSSG0901）. World J Surg 2015; 39: 2734‒41.

13）Lee HJ, Hyung WJ, Yang HK, et al: Short‒term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer（KLASS‒02‒RCT）. Ann Surg 2019; 270: 983‒91.

14）Hu Y, Huang C, Sun Y, et al: Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol 2016; 34: 1350‒7.

15）Yu J, Huang C, Sun Y, et al: Effect of Laparoscopic vs Open Distal Gastrectomy on 3‒Year Disease‒Free Survival in Patients With Locally Advanced Gastric Cancer: the CLASS‒01 Randomized Clinical Trial. JAMA 2019; 321: 1983‒92.

16）Hyung WJ, Yang HK, Park YK, et al: Long‒Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS‒02‒RCT Randomized Clinical Trial. J Clin Oncol 2020; 38: 3304‒13.

17）Uyama I, Suda K, Nakauchi M, et al: Clinical advantages of robotic gastrectomy for clinical stage Ⅰ/Ⅱ gastric cancer: a multi‒institutional prospective single‒arm study. Gastric Cancer 2019; 22: 377‒85.

18）Hikage M, Tokunaga M, Makuuchi R, et al: Comparison of Surgical Outcomes Between Robotic and Laparoscopic Distal Gastrectomy for cT1 Gastric Cancer. World J Surg 2018; 42: 1803‒10.

19）Tada M, Murakami A, Karita M, et al: Endoscopic resection of early gastric cancer. Endoscopy 1993; 25: 445‒50.

20）Inoue H, Takeshita K, Hori H, et al: Endoscopic mucosal resection with a cap‒fitted panendoscope for esophagus, stomach, and colon mucosal lesions. Gastrointest Endosc 1993; 39: 58‒62.

21）Hirao M, Masuda K, Asanuma T, et al: Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic saline‒epinephrine. Gastrointest Endosc 1988; 34: 264‒9.

22）Ono H, Kondo H, Gotoda T, et al: Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001; 48: 225‒9.

23）Ono H, Hasuike N, Inui T, et al: Usefulness of a novel electrosurgical knife, the insulation‒tipped diathermic knife‒2, for endoscopic submucosal dissection of early gastric cancer. Gastric Cancer 2008; 11: 47‒52.

24）下田忠和，九嶋亮治，小野裕之：【潰瘍合併早期胃癌の診断と治療】ESD標本における消化性潰瘍と生検瘢痕との鑑別．胃と腸 2013；48：16‒24．

25）Gotoda T, Yanagisawa A, Sasako M, et al: Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3: 219‒25.

26）Hirasawa T, Gotoda T, Miyata S, et al: Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated‒type early gastric cancer. Gastric Cancer 2009; 12: 148‒52.

27）Gotoda T, Iwasaki M, Kusano C, et al: Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg 2010; 97: 868‒71.

28）Hasuike N, Ono H, Boku N, et al: A non‒randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal‒type gastric cancer（cT1a）: the Japan Clinical Oncology Group study（JCOG0607）. Gastric Cancer 2018; 21: 114‒23.

29）Takizawa K, Ono H, Hasuike N, et al: A nonrandomized, single‒arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group Study（JCOG1009/1010）. Gastric Cancer 2021; 24: 479-91.

30）Sekiguchi M, Suzuki H, Oda I, et al: Favorable long‒term outcomes of endoscopic submucosal dissection for locally recurrent early gastric cancer after endoscopic resection. Endoscopy 2013; 45: 708‒13.

31）Jung DH, Bae YS, Yoon SO, et al: Poorly Differentiated Carcinoma Component in Submucosal Layer Should be Considered as an Additional Criterion for Curative Endoscopic Resection of Early Gastric Cancer. Ann Surg Oncol 2015; 22 Suppl 3: S772‒7.

32）Nakajima T, Oda I, Gotoda T, et al: Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance? Gastric Cancer 2006; 9: 93‒8.

33）Gotoda T, Sasako M, Ono H, et al: Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. Br J Surg 2001; 88: 444‒9.

34）日本ヘリコバクター学会ガイドライン作成委員会編：H.pylori感染の診断と治療のガイドライン 2016年改訂版．先端医学社，東京．

35）Fukase K, Kato M, Kikuchi S, et al: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-7.

36）Choi IJ, Kook MC, Kim YI, et al: Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med 2018; 378: 1085-95.

37）Eguchi T‚ Gotoda T, Oda I, et al: Is endoscopic one piece mucosal resection essential for early gastric cancer? Dig Endosc 2003; 15: 113‒6.

38）Takizawa K, Hatta W, Gotoda T, et al: Recurrence Patterns and Outcomes of Salvage Surgery in Cases of Non-Curative Endoscopic Submucosal Dissection without Additional Radical Surgery for Early Gastric Cancer. Digestion 2019; 99: 52-8.

39）日本胃癌学会編：胃癌治療ガイドライン　医師用 2018年1月改訂．第5版，金原出版，東京，24．

40）Hatta W, Gotoda T, Oyama T, et al: A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: “eCura system”. Am J Gastroenterol 2017; 112: 874‒81.

41）Yamada Y, Higuchi K, Nishikawa K, et al: Phase Ⅲ study comparing oxaliplatin plus S‒1 with cisplatin plus S‒1 in chemotherapy‒naïve patients with advanced gastric cancer. Ann Oncol 2015; 26: 141‒8.

42）Kang YK, Chin K, Chung HC, et al: S‒1 plus leucovorin and oxaliplatin versus S‒1 plus cisplatin as first‒line therapy in patients with advanced gastric cancer（SOLAR）: a randomised, open‒label, phase 3 trial. Lancet Oncol 2020; 21: 1045‒56.

43）Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5‒fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37‒41.

44）Glimelius B, Hoffman K, Haglund U, et al: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994; 5: 189‒90.

45）Pyrhönen S, Kuitunen T, Nyandoto P, et al: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate（FEMTX）plus supportive care with supportive care alone in patients with non‒resectable gastric cancer. Br J Cancer 1995; 71: 587‒91.

46）Boku N, Yamamoto S, Fukuda H, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S‒1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063‒9.

47）Koizumi W, Narahara H, Hara T, et al: S‒1 plus cisplatin versus S‒1 alone for first‒line treatment of advanced gastric cancer（SPIRITS trial）: a phase Ⅲ trial. Lancet Oncol 2008; 9: 215‒21.

48）Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‒positive advanced gastric or gastro‒oesophageal junction cancer（ToGA）: a phase 3, open‒label, randomised controlled trial. Lancet 2010; 376: 687‒97.

49）Ohtsu A, Shah MA, Van Cutsem E, et al: Bevacizumab in combination with chemotherapy as first‒line therapy in advanced gastric cancer: a randomized, double‒blind, placebo‒controlled phase Ⅲ study. J Clin Oncol 2011; 29: 3968‒76.

50）Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36‒46.

51）Shah MA, Bang YJ, Lordick F, et al: Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2‒Negative, MET‒Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncol 2017; 3: 620‒7.

52）Yoon HH, Bendell JC, Braiteh FS, et al: Ramucirumab combined with FOLFOX as front‒line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double‒blind, multicenter Phase Ⅱ trial. Ann Oncol 2016; 27: 2196‒203.

53）Kurokawa Y, Sugimoto N, Miwa H, et al: Phase Ⅱ study of trastuzumab in combination with S‒1 plus cisplatin in HER2‒positive gastric cancer（HERBIS‒1）. Br J Cancer 2014; 110: 1163‒8.

54）Miura Y, Sukawa Y, Hironaka S, et al: Five‒weekly S‒1 plus cisplatin therapy combined with trastuzumab therapy in HER2‒positive gastric cancer: a phase Ⅱ trial and biomarker study（WJOG7212G）. Gastric Cancer 2018; 21: 84‒95.

55）Rivera F, Romero C, Jimenez‒Fonseca P, et al: Phase Ⅱ study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first‒line treatment of HER2‒positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol 2019; 83: 1175‒81.

56）Yuki S, Shinozaki K, Kashiwada T, et al: Multicenter phase Ⅱ study of SOX plus trastuzumab for patients with HER2（＋）metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. Cancer Chemother Pharmacol 2020; 85: 217‒23.

57）Takahari D, Chin K, Ishizuka N, et al: Multicenter phase Ⅱ study of trastuzumab with S‒1 plus oxaliplatin for chemotherapy‒naïve, HER2‒positive advanced gastric cancer. Gastric Cancer 2019; 22: 1238‒46.

58）Ryu MH, Yoo C, Kim JG, et al: Multicenter phase Ⅱ study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer 2015; 51: 482‒8.

59）Thuss‒Patience PC, Kretzschmar A, Bichev D, et al: Survival advantage for irinotecan versus best supportive care as second‒line chemotherapy in gastric cancer‒‒a randomised phase Ⅲ study of the Arbeitsgemeinschaft Internistische Onkologie（AIO）. Eur J Cancer 2011; 47: 2306‒14.

60）Kang JH, Lee SI, Lim DH, et al: Salvage chemotherapy for pretreated gastric cancer: a randomized phase Ⅲ trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30: 1513‒8.

61）Ford HE, Marshall A, Bridgewater JA, et al: Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma（COUGAR‒02）: an open‒label, phase 3 randomised controlled trial. Lancet Oncol 2014; 15: 78‒86.

62）Hironaka S, Ueda S, Yasui H, et al: Randomized, open‒label, phase Ⅲ study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013; 31: 4438‒44.

63）Wilke H, Muro K, Van Cutsem E, et al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro‒oesophageal junction adenocarcinoma（RAINBOW）: a double‒blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224‒35.

64）Shitara K, Takashima A, Fujitani K, et al: Nab‒paclitaxel versus solvent‒based paclitaxel in patients with previously treated advanced gastric cancer（ABSOLUTE）: an open‒label, randomised, non‒inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2: 277‒87.

65）Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S‒1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810‒20.

66）Sasako M, Sakuramoto S, Katai H, et al: Five‒year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S‒1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer. J Clin Oncol 2011; 29: 4387‒93.

67）Bang YJ, Kim YW, Yang HK, et al: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy（CLASSIC）: a phase 3 open‒label, randomised controlled trial. Lancet 2012; 379: 315‒21.

68）Fuse N, Bando H, Chin K, et al: Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase Ⅱ study. Gastric Cancer 2017; 20: 332-40.

69）Yoshida K, Kodera Y, Kochi M, et al: Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage Ⅲ Gastric Cancer: Interim Analysis of JACCRO GC‒07, a Randomized Controlled Trial. J Clin Oncol 2019; 37: 1296‒304.

70）Park SH, Lim DH, Sohn TS, et al: ARTIST 2 investigators. A randomized phase Ⅲ trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol 2021; 32: 368-74.

71）Yoshikawa T, Terashima M, Mizusawa J, et al: Four courses versus eight courses of adjuvant S‒1 for patients with stage Ⅱ gastric cancer（JCOG1104）: an open‒label, phase 3, non‒inferiority, randomised trial. Lancet Gastroenterol Hepatol 2019; 4: 208‒16.

72）Terashima M, Iwasaki Y, Mizusawa J, et al: Randomized phase Ⅲ trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study （JCOG0501）．Gastric Cancer 2019; 22: 1044-52.

73）日本緩和医療学会ウェブサイト．Available at https://www.jspm.ne.jp/proposal/

74）Cherny NI, Catane R, Kosmidis P: ESMO takes a stand on supportive and palliative care. Ann Oncol 2003; 14: 1335‒7.

75）Tanaka R, Lee SW, Kawai M, et al: Protocol for enhanced recovery after surgery improves short‒term outcomes for patients with gastric cancer: a randomized clinical trial. Gastric cancer 2017; 20: 861‒71.

76）Shimizu N, Oki E, Tanizawa Y, et al: Effect of early oral feeding on length of hospital stay following gastrectomy for gastric cancer: a Japanese multicenter, randomized controlled trial. Surg Today 2018; 48: 865‒74.

77）Kodera Y, Ito S, Yamamura Y, et al: Follow‒up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol 2003; 10: 898‒902.

78）Park CH, Park JC, Chung H, et al: Impact of the Surveillance Interval on the Survival of Patients Who Undergo Curative Surgery for Gastric Cancer. Ann Surg Oncol 2016; 23: 539‒45.

79）Takahashi Y, Takeuchi T, Sakamoto J, et al: The usefulness of CEA and/or CA19‒9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer 2003; 6: 142‒5.

80）Lee JH, Kim HI, Kim MG, et al: Recurrence of gastric cancer in patients who are diseasefree for more than 5 years after primary resection. Surgery 2016; 159: 1090-8.